Marksans Pharma Limited
UTI Mutual Fund decreased its stake in Marksans Pharma from 2.49% to 2.11%, selling 17,45,067 shares. The shares were valued at ₹46.59 Cr based on the closing price of ₹267.10 apiece.
A pharmaceutical formulation company engaged in the development and manufacture of a diverse range of drugs across multiple therapeutic areas for domestic and international markets. Marksans Pharma produces generic medications and branded formulations with a focus on quality and regulatory compliance. The company operates modern manufacturing facilities designed to meet stringent pharmaceutical production standards and global quality requirements.
India's oldest and most storied asset manager, founded in 1963 as the Unit Trust of India under an Act of Parliament. Now manages over Rs 3.5 lakh crore with backing from four public sector institutions: LIC, SBI, Bank of Baroda, and Punjab National Bank. CIO Vetri Subramaniam is a long-term compounder with a consistent quality tilt and clear articulation of process.